Metronidazole addition improves treatment of acute PID in women

USA: Metronidazole should be routinely added to ceftriaxone and doxycycline for the treatment of women with acute pelvic inflammatory disease (PID), a recent study in the journal Clinical Infectious Diseases has suggested.
According to the study, the addition of metronidazole was well tolerated and resulted in reduced endometrial anaerobes, decreased M. genitalium and reduced pelvic tenderness compared to ceftriaxone and doxycycline.
Anaerobic organisms are important pathogens in acute PID. PID regime of a single dose of ceftriaxone and doxycycline for 14 days, which is currently recommended, has limited anaerobic activity. The need for broader anaerobic coverage is unknown and concerns have been raised about the tolerability of metronidazole. Harold C Wiesenfeld, Magee-Womens Research Institute, Pittsburgh, PA, USA, and colleagues conducted a randomized, double-blind placebo-controlled trial comparing ceftriaxone 250 mg IM single dose and doxycycline for 14 days, with or without 14 days of metronidazole in women with acute PID. A total of 233 women were enrolled (116 to metronidazole and 117 to placebo).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.